𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacological and Pharmacokinetic Evaluation of EXP3312, an Orally-active Non-peptide Angiotensin II-Receptor Antagonist

✍ Scribed by Y. NANCY WONG; PANCRAS C. WONG

Book ID
118110267
Publisher
Pharmaceutical Press
Year
1996
Tongue
English
Weight
474 KB
Volume
48
Category
Article
ISSN
2042-7158

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Effects of cimetidine on pharmacokinetic
Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist
✍ M. R. Goldberg; M. W. Lo; T. E. Bradstreet; M. A. Ritter; P. HΓΆgland πŸ“‚ Article πŸ“… 1995 πŸ› Springer 🌐 English βš– 512 KB

This was a 2-period randomized, crossover study in 8 healthy males to determine the effects of cimetidine (400 mg q.i.d. for 6 days) on the pharmacokinetics and pharmacodynamic effects of the angiotensin II receptor antagonist, losartan (100 mg). Cimetidine increased the AUC for losartan 18% without

The pharmacokinetics and metabolism of D
The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs
✍ Y. N. Wong; K. A. Holm; D. L. Burcham; S.-M. Huang; C. Y. Quon πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 481 KB πŸ‘ 1 views

DuP 532, 2-propy1-4-pentafluoroethyl-l-[ [2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylJ imidazole-5-carboxylic acid, is an orally active, non-peptide angiotensin I1 (AII) receptor antagonist. DuP 532 is more potent and longer acting than losartan, another A11 receptor antagonist currently undergoing ph